Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

作者: Teresa Troiani , Stefania Napolitano , Carminia Maria Della Corte , Giulia Martini , Erika Martinelli

DOI: 10.1136/ESMOOPEN-2016-000088

关键词:

摘要: Epidermal growth factor receptor (EGFR) plays a key role in tumour evolution, proliferation and immune evasion, is one of the most important targets for biological therapy, especially non-small-cell lung cancer (NSCLC) colorectal (CRC). In past 15 years, several EGFR antagonists have been approved treatment NSCLC metastatic CRC (mCRC). To optimise use anti-EGFR agents clinical practice, various molecular biomarkers investigated, thus moving their indication from unselected to selected populations. Nowadays, drugs represent gold-standard therapy harbouring activating mutation RAS wild-type mCRC. Their efficacy limited by presence intrinsic resistance or onset acquired resistance. this review, we provide an overview antitumour activity inhibitors mechanisms resistance, focusing on development personalised approach through 15 years preclinical research.

参考文章(99)
Kenneth S Thress, Cloud P Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J Carl Barrett, Pasi A Jänne, Geoffrey R Oxnard, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M Nature Medicine. ,vol. 21, pp. 560- 562 ,(2015) , 10.1038/NM.3854
Feng Wei, Jin-Pu Yu, Wen-Wen Yu, Shui Cao, Lei Han, Jie-Ying Chen, Ya-Nan Cheng, Xin-Wei Zhang, Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis Cancer biology and medicine. ,vol. 12, pp. 126- 139 ,(2015) , 10.7497/J.ISSN.2095-3941.2015.0021
Teresa Troiani, Stefania Napolitano, Giulia Martini, Erika Martinelli, Claudia Cardone, Nicola Normanno, Donata Vitagliano, Floriana Morgillo, Francesca Fenizia, Matilde Lambiase, Luigi Formisano, Roberto Bianco, Davide Ciardiello, Fortunato Ciardiello, Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. Clinical Cancer Research. ,vol. 21, pp. 4153- 4164 ,(2015) , 10.1158/1078-0432.CCR-15-0211
Giulia Siravegna, Benedetta Mussolin, Michela Buscarino, Giorgio Corti, Andrea Cassingena, Giovanni Crisafulli, Agostino Ponzetti, Chiara Cremolini, Alessio Amatu, Calogero Lauricella, Simona Lamba, Sebastijan Hobor, Antonio Avallone, Emanuele Valtorta, Giuseppe Rospo, Enzo Medico, Valentina Motta, Carlotta Antoniotti, Fabiana Tatangelo, Beatriz Bellosillo, Silvio Veronese, Alfredo Budillon, Clara Montagut, Patrizia Racca, Silvia Marsoni, Alfredo Falcone, Ryan B Corcoran, Federica Di Nicolantonio, Fotios Loupakis, Salvatore Siena, Andrea Sartore-Bianchi, Alberto Bardelli, Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients Nature Medicine. ,vol. 21, pp. 795- 801 ,(2015) , 10.1038/NM.3870
Jordi Remon, David Planchard, AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. Future Oncology. ,vol. 11, pp. 3069- 3081 ,(2015) , 10.2217/FON.15.250
J. Baselga, D. Pfister, M.R. Cooper, R. Cohen, B. Burtness, M. Bos, G. D’Andrea, A. Seidman, L. Norton, K. Gunnett, J. Falcey, V. Anderson, H. Waksal, J. Mendelsohn, Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin Journal of Clinical Oncology. ,vol. 18, pp. 904- 914 ,(2000) , 10.1200/JCO.2000.18.4.904
Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber, Epidermal growth factor receptor mutations in lung cancer Nature Reviews Cancer. ,vol. 7, pp. 169- 181 ,(2007) , 10.1038/NRC2088
Filippo Pietrantonio, Fausto Petrelli, Andrea Coinu, Maria Di Bartolomeo, Karen Borgonovo, Claudia Maggi, Mary Cabiddu, Roberto Iacovelli, Ilaria Bossi, Veronica Lonati, Mara Ghilardi, Filippo de Braud, Sandro Barni, Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis European Journal of Cancer. ,vol. 51, pp. 587- 594 ,(2015) , 10.1016/J.EJCA.2015.01.054
Andrea Bertotti, Giorgia Migliardi, Francesco Galimi, Francesco Sassi, Davide Torti, Claudio Isella, Davide Corà, Federica Di Nicolantonio, Michela Buscarino, Consalvo Petti, Dario Ribero, Nadia Russolillo, Andrea Muratore, Paolo Massucco, Alberto Pisacane, Luca Molinaro, Emanuele Valtorta, Andrea Sartore-Bianchi, Mauro Risio, Lorenzo Capussotti, Marcello Gambacorta, Salvatore Siena, Enzo Medico, Anna Sapino, Silvia Marsoni, Paolo M Comoglio, Alberto Bardelli, Livio Trusolino, None, A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discovery. ,vol. 1, pp. 508- 523 ,(2011) , 10.1158/2159-8290.CD-11-0109